Glucose and H 2 O 2 dual-sensitive nanogels for enhanced glucose-responsive insulin delivery
More serious but less common adverse effects include acute pancreatitis (seek urgent medical attention for severe, persistent abdominal pain), gallbladder disease, and risk of dehydration or acute kidney injury from prolonged vomiting Hypoglycaemia risk : When combined with insulin or sulfonylureas, GLP-1 receptor agonists increase the risk of hypoglycaemia [1] Long-term safety : The extended safety profile in older populations and those with established dementia requires further investigation Patients should report suspected side effects via the MHRA Yellow Card Scheme and discuss both the established benefits for metabolic health and the investigational nature of any cognitive effects with their healthcare provider
Is alcohol safe while taking Wegovy for weight loss
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade